Skip to main content

HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) Prophylaxis

CBE ID
0405
Endorsed
New or Maintenance
Is Under Review
No
Measure Description

Percentage of patients aged 6 weeks or older with a diagnosis of HIV/AIDS, who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis

  • Measure Type
    Electronic Clinical Quality Measure (eCQM)
    MAT output not attached
    Attached
    Data dictionary not attached
    No
    Numerator

    Numerator 1: Patients who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis within 3 months of CD4 count below 200 cells/mm3

    Numerator 2: Patients who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis within 3 months of CD4 count below 500 cells/mm3 or a CD4 percentage below 15%

    Numerator 3: Patients who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis at the time of HIV diagnosis

    Report a rate for each numerator (e.g., Numerator 1/Denominator 1, etc.) and a total rate (Total Numerator/Total Denominator)

    Denominator

    Denominator 1. All patients aged 6 years and older with a diagnosis of HIV/AIDS and a CD4 count below 200 cells/mm3, who had at least two visits during the measurement year, with at least 90 days in between each visit; and, 

    Denominator 2. All patients aged 1 through 5 years of age with a diagnosis of HIV/AIDS and a CD4 count below 500 cells/mm3 or a CD4 percentage below 15%, who had at least two visits during the measurement year, with at least 90 days in between each visit; and, 

    Denominator 3. All patients aged 6 weeks through 12 months with a diagnosis of HIV, who had at least two visits during the measurement year, with at least 90 days in between each visit

    Total denominator: The sum of the three denominators

    Exclusions

    Denominator 1 Exclusion: Patient did not receive PCP prophylaxis because there was a CD4 count above 200 cells/mm3 during the three months after a CD4 count below 200 cells/mm3

    Denominator 2 Exclusion: Patient did not receive PCP prophylaxis because there was a CD4 count above 500 cells/mm3 or CD4 percentage above 15% during the three months after a CD4 count below 500 cells/mm3 or CD4 percentage below 15%

    All information required to stratify the measure results
    Off
    All information required to stratify the measure results
    Off
    Testing Data Sources
  • Risk adjustment approach
    Off
    Risk adjustment approach
    Off
    Conceptual model for risk adjustment
    Off
    Conceptual model for risk adjustment
    Off
  • Most Recent Endorsement Activity
    Endorsed Infectious Disease Endorsement Maintenance Project
    Initial Endorsement
    Next Planned Maintenance Review
    Fall 2023
    Endorsement Status
    E&M Committee Rationale/Justification

    Steward no longer seeking to maintain endorsement

    Last Updated
    Removal Date
  • Do you have a secondary measure developer point of contact?
    Off
    The measure developer is NOT the same as measure steward
    On
    Steward Organization Email
    Steward Phone Number
    Steward Organization Copyright

    This Measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposed, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, (on behalf of the Consortium) or NCQA. Neither the AMA, NCQA, Consortium nor its members shall be responsible for any use of the Measure.

    © 2012 American Medical Association and National Committee for Quality Assurance. All Rights Reserved

    Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

  • Detailed Measure Specifications
    No
    Logic Model
    Off
    Impact and Gap
    No
    Feasibility assessment methodology and results
    No
    Address health equity
    No
    Measure’s use or intended use
    No
    508 Compliance
    Off
    If no, attest that all information will be provided in other fields in the submission.
    Off